HOME
>
臨床医学：内科
>
膠原病/リウマチ
> 生物学的製剤による難病の治療革命

生物学的製剤による難病の治療革命

出版社：	日本医学出版
著者：	田中良哉／編
発行日：	2009-09-10
分野：	臨床医学：内科 > 膠原病/リウマチ
ISBN：	9784902266436
電子書籍版：	2009-09-10 （初版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：約3営業日

3,080 円(税込)

購入する

電子書籍

章別単位で購入

ブラウザ、アプリ閲覧

3,080 円(税込)

購入する

商品紹介

生物学的製剤による治療革命は、自己免疫疾患、悪性腫瘍、移植拒絶に留まらず、炎症性腸疾患、多発性硬化症などの神経疾患、天疱瘡、乾癬などの皮膚疾患、ベーチェット病眼病変、小児疾患などの多様な難病へも誘導され、各領域で治療のブレークスルーを引き起こす勢いである。本書では、生物学的製剤の領域の斯界の先生方にご執筆戴き、病態と治療の新しい考え方、新規治療導入の実際、今後の新展開に至るまでをまとめた。

目次

生物学的製剤による難病の治療革命

―目次―

I. 関節リウマチ治療を一変させたTNF阻害療法
　インフリキシマブの使用の実際と安全性
　イタネルセプトの使用の実際と安全性
　完全ヒト型坑TNF抗体（アダリムマブ、ゴリムマブ）
　坑IL-6R抗体（トリシズマブ）
　寛解導入と治療の可能性
　関節破壊進行の完全制御
　生命予後の改善

II. 期待される多様な分野への臨床応用
　炎症性腸疾患
　神経疾患（多発性硬化症）
　血液・腫瘍疾患
　皮膚疾患
　眼疾患（ベーチェット病）
　小児疾患

III. 現在申請中・開発中の生物学的製剤
　CTLA4-Ig（アバタセプト）
　坑B細胞抗体
　坑B細胞表面分子療法（ベリムマブ、アタシセプト）
　坑RANKL抗体製剤（デノスマブ）

IV. イノベイティブ新薬開発促進の支援
　PMDAの取り組み

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 関節リウマチ治療を一変させたTNF阻害療法

P.7 掲載の参考文献

1) O'Dell JR : N Engl J Med 340 : 310, 1999

2) Choy EH, Panayi GS : N Engl J Med 344 : 907, 2001

3) 日本リウマチ学会http://www.ryumachi-jp. com/

4) Goekoop-Ruiterman YP et al : Ann Rheum Dis 66 : 1227, 2007

5) Goekoop-Ruiterman YP et al : Intern Med 146 : 406, 2007

6) Takeuchi T et al : Ann Rheum Dis 67 : 189, 2008

7) Tokuda et al : Intern Med 47 : 915, 2008

8) Harigai M et al : N Engl J Med 357 : 1874, 2007

9) Komano Y et al : Arthritis Rheum 54 : S516, 2006

10) Miyasaka N et al : Mod Rheumatol 15 : 4, 2005

11) Komano Y et al : Arthritis Rheum 54 : S516, 2006

12) Nathan DM et al : J Gastroenterol Hepatol 21 : 1366, 2006

13) Chung ES et al : Circulation 107 : 3133, 2003

14) Kwon HJ et al : Ann Intern Med 138 : 807, 2003

15) Mohan N et al : Arthritis Rheum 44 : 2862, 2001

16) Cheifetz A et al : Am Con of Gastroenterology 98 : 1315, 2003

P.17 掲載の参考文献

1) Miyasaka N, Takeuchi T, Eguchi K : Guidelines for the proper use of etanercept in Japan. Mod Rheumatol ; 16 : 63, 2006

2) Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al : Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial. Lancet ; 363 : 675, 2004

3) Van Der Kooij SM, Van Der Bijl AE, Allaart CF, Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Gerards AH, et al : Remission Induction in Early Rheumatoid Arthritis (RA) with Initial Infliximab (IFX) and Methotrexate (MTX) Therapy : The Disease Course After IFX Discontinuation in The Best Trial. Arthritis Rheum ; 54 : S302, 2006

4) 日本リウマチ学会ホームページ : 関節リウマチ (RA) に対するTNF阻害療法施行ガイドライン (改訂版), http://www.ryumachi-jp.com/info/080201.html.

5) Koike R, Takeuchi T, Eguchi K, Miyasaka N : Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol ; 17 : 451, 2007

6) Vol.9, 全例調査の中間報告および死亡症例についてエ. ワイス株式会社, 武田薬品工業株式会社, 2008年12月

7) Harigai M : Efficacy and safety of etanercept in Japan : results from the postmarketing surveillance with 14,000 rheumatoid arthritis patients. Mod Rheumatol ; 18 : S9, 2008

8) Vol.8, ニューモシスチス肺炎および間質性肺炎についての検討結果 (抜粋). ワイス株式会社, 武田薬品工業株式会社, 2008年4月

9) Harigai M, Koike R, Miyasaka N : Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med ; 357 : 1874, 2007

P.24 掲載の参考文献

1) Anderson P J : Tumor necrosis factor inhibitors : clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34 : 19-22, 2005

2) den Broeder A A, L A Joosten, Saxne T et al : Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis : effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61 : 311-318, 2002

3) Weinblatt M E, Keystone E C, Furst D E et al : Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis : ARMADA 4 year extended study. Ann Rheum Dis 65 : 753-759, 2006

4) Keystone E C, Kavanaugh A E Sharp J T et al : Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy : arandomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 : 1400-1411, 2004

5) Burmester G R, Mariette X, Montecucco C et al : Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice : the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 66 : 732-739, 2007

6) Burmester G R, Ferraccioli G, Flipo R M et al : Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59 : 32-41, 2008

7) van de Putte L B, Atkins C, Malaise M et al : Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63 : 508-516, 2004

8) Miyasaka N : Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation : the CHANGE study. Mod Rheumatol 18 : 252-262, 2008

9) Breedveld F C, Weisman M H, Kavanaugh A Fet al : The PREMIER study : amulticenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 : 26-37, 2006

10) Mease P J, Gladman D D, Ritchlin C T et al : Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis : results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 : 3279-3289, 2005

11) Gladman D D, Mease P J, Ritchlin C T et al : Adalimumab for long-term treatment of psoriatic arthritis : forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial, Arthritis Rheum 56 : 476-488, 2007

12) van der Heijde D, Kivitz A, Schiff M H et al : Efficacy and safety of adalimumab in patients with ankylosing spondylitis : results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54 : 2136-2146, 2006

13) van der Heijde D, Pangan A I., Schiff M H et al : Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67 : 1218-1221, 2008

14) Furst D E M H Schiff, R M Fleischmann et al : Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis. results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30 : 2563-2571, 2003

15) Schiff M H, Burmester G R, Kent J D et al : Safety analyses of adalimumab (HUMIRA) in Efficacy and safety of adalimumab in patients with ankylosing spondylitis : results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54 : 2136-2146, 2006

16) Geborek P, Bladstrom A, Turesson C et al : Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 : 699-703, 2005.

17) Bartelds G M, Wolbink G J, Stapel S et al : High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 65 : 1249-1250, 2006

18) Kay J E L Matteson, B Dasgupta et al : Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate : arandomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58 : 964-975, 2008

P.34 掲載の参考文献

1) Nemeth E, Rivera S, Gabayan V et al : IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 : 1271-1276, 2004

2) Nakahara H, Song J, Sugimoto M et al : Anti-interleukin-6 receptor antibody therapy reduced vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48 : 1521-1529, 2003

3) Iwakura Y, Ishigame H : The IL-23/IL-17 axis in inflammation. J Clin Invest 116, 1218-1222, 2006

4) Taga T, Kishimoto T : gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15 : 797-819, 1997

5) Nishimoto N, Yoshizaki Y, Maeda K et al : Toxicity, phamacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis : phase I/II clinical study. J Rheumatol 30 : 1426-1435, 2003

6) Nishimoto N, Yoshizaki K, Miyasaka N et al : Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor anti-body : amulticenter, double-blind, placebo-controlled trial. Arthritis Rheum 50 : 1761-1769, 2004

7) Maini RN, Taylor PC, Szechinski J et al : Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 : 2817-2829, 2006

8) Nishimoto N, Hashimoto J, Miyasaka N et al : Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) : evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 66 : 1162-1167, 2007

9) Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN : Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358 . 24-29, 2001

10) Okuda Y, Takasugi K : Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid a amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54 : 2997-3000, 2006

11) Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ : TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168 : 4620-4627, 2002

12) Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T : Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis : arandomised, double-blind, placebo-controlled, withdrawal phase m triaL Lancet 371 (9617) : 998-1006, 2008

13) Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T : A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 : 989-996, 2004

14) Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K : Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Stilr s disease. Arthritis Rheum 46 : 3388-3389, 2002

15) Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N : A case report of a patient with refractory adultonset Still's disease who was successfully treated with tocilizumab over 6 years (in press)

16) Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T : Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 58 : 1197-1200, 2008

P.42 掲載の参考文献

1) Yamanaka H, Tanaka Y et al : Retrospective clinical study on the notable ethcacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 17 : 28-32, 2007

2) Tanaka Y, Takeuchi T, Inoue E et al : Retrospective clinical study on the notable efficacy and related factors of in fiximab therapy in a rheumatoid arthritis management group in Japan : one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol 18 (2) : 146-152, 2008

3) Klareskog L, van der Heijde D, de Jager JP et al : TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial. Lancet 363 : 675-681, 2004

4) van der Heijde D, Klareskog L, Rodriguez-Valverde V et al : TEMPO Study lnvestigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis : two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54 : 1063-1074, 2006

5) Breedveld FC, Weisman MH, Kavanaugh AF et al : The PREMIER study : amulticenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 : 26-37, 2006

6) Quinn MA, Conaghan PG et al : Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal : results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52 : 27-35, 2005

7) van der Bijl AE, Goekoop-Ruiterman YP et al : Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 56 : 2129-2134, 2007

8) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al : Patient preferences for treatment : report from a randomised comparison of treatment strategies in early rheumatoid arthritis (Best trial). Ann Rheum Dis 66 : 1227-1232, 2007

9) Nawata M, Saito K, Nakayamada S et al : Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol, 2008 (in print)

P.52 掲載の参考文献

1) Pinals RS et al : Arthritis Rheum 24 : 1308-1315, 1981

2) Makinen H et al : Clin Exp Rheumatol 24 (Supple 43) : SS22-SS28, 2006

3) Yamanaka H et al. : Mod Rheumatol., 17 : 28-32, 2007.

4) 名和田雅夫ら : 最新医学別冊新しい診断と治療のABC関節リウマチ改訂第2版, 279-286, 2008

5) Quinn MA et al : Arthritis Rheum 52 : 27-35, 2005

6) Ostergaard M et al : Arthritis Rheum 48 : 2128-2131, 2003

7) 勝呂徹 : 整形外科医のための最新関節リウマチ治療-生物学的製剤の使い方と注意点 : 85-86, 2007

8) ACR Subcommittee on Rheumatoid Arthritis Guidelines : Arthritis Rheum 46 : 328-346, 2002

9) 駒野有希子ら : 医学のあゆみ221 : 463-466, 2007

10) Maini RN et al : Arthritis Rheum 50 : 1051-1065, 2004

11) Smolen JS et al : Arthritis and Rheum 52 : 1020-1030, 2005

12) EWilliam, St Clair et al : Arthritis Rheum 50 : 3432-3443, 2004

13) Smolen JS et al : Arthritis Rheum 54 : 702-710, 2006

14) Goekoop-Ruiterman YP et al : Arthritis Rheum 52 : 3381-3390, 2005

15) van der Bijl AE et al. Arthritis Rheum 56 : 2129-2134, 2007

16) Genovese MC et al : Arthritis Rheum 46 : 1443-1450, 2002

17) Klareskog L et al : Lancet 363 : 675-681, 2004

18) van der Heijde D et al : Arthritis and Rheum 54 : 1063-1074, 2006

19) Landewe R et al : Arthritis Rheum 54 : 3119-3125, 2006

P.60 掲載の参考文献

1) Cobbs S, Anderson F, Bauer W : Length of life and cause of death in rheumatoid arthritis. N Engl J Med 249 (14) : 553-556, 1953

2) Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA : The mortality of rheumatoid arthritis. Arthritis Rheum. 37 (4) : 481- 494, 1994

3) Mikuls TR, Saag KG, Criswell LA, Merlino LA, Kaslow RA, Shelton BJ, Cerhan JR : Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women : results from the Iowa Women's Health Study. Ann Rheum Dis 61 (11) : 994-999, 2002

4) Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, Matteson EL : Survival in rheumatoid arthritis : a population-based analysis of trends over 40 years. Arthritis Rheum 48 (1) : 54-58. 2003

5) Hakoda M, Oiwa H, Kasagi F, Masunari N, Yamada M, Suzuki G, Fujiwara S : Mortality of rheumatoid arthritis in Japan : alongitudinal cohort study. Ann Rheum Dis 64 (10) : 1451-1455. 2005

6) Chehata JC, Hassell AB, Clarke SA, Mattey DL, Jones MA, Jones PW, Dawes PT : Mortality in rheumatoid arthritis : relationship to single and composite measures of disease activity. Rheumatology (Oxford) 40 (4) : 447-452, 2001

7) Pincus T, Callahan LF : Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity. J Rheumatol 13 (5) : 841-845, 1986

8) Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, Gabriel SE : The risk of congestive heart failure in rheumatoid arthritis : apopulation-based study over 46 years. Arthritis Rheum 52 (2) : 412-420, 2005

9) 宗圓聰 : RA患者の死亡率と死因. リウマチ科 37 (2) : 164-168, 2007

10) Shinomiya F, Mima N, Nanba K, Tani K, Nakano S, Egawa H, Sakai T, Miyoshi H, Hamada D : Life expectancies of Japanese patients with rheumatoid arthritis : a review of deaths over a 20-year period. Mod Rheumatol 18 (2) : 165-169, 2008

11) Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F : Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis : a nested, case-control study. Arthritis Rheum 59 (8) : 1090-1096, 2008

12) Wolfe F, Cathey MA : Analysis of methotrexate treatment effect in a longitudinal observational study : utility of cluster analysis. J Rheumatol 18 (5) : 672-727, 1991

13) Kremer JM : Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate : followup after amean of 13. 3 years. Arthritis Rheum 40 (5) : 984-985, 1997

14) Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F : Methotrexate and mortality in patients with rheumatoid arthritis : a prospective study. Lancet 359 (9313) : 1173-1177, 2002

15) Michaud K, Wolfe F : Reduced mortality among RA patients treated with anti-TNF therapy and methotrexate. Arthritis Rheum 52 : S145. 2005 (abstract)

16) Greenberg J, Lin SL, Decktor D et al : Association of duration of TNF antagonist treatment with reduction in cardiovascular outcomes in RA patients. Arthritis Rheum 54 : S422, 2006 (abstract)

17) Dixon WG, Watson KD, Lunt M, Hyrich KL, Rates of Myocardial Infarction (MI) and Cerebrovascular Accident (CVA) In Patients with Rheumatoid Arthritis (RA) Treated with Anti-TNF Therapy : Results From the British Society for Rheumatology Biologics Register (BSRBR). Arthritis Rheum 54 : S311, 2006 (abstract)

18) Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P : Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 66 (5) : 670-5. 2007

19) Jacobsson LT, Turesson C, Giffe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P : Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (7) : 1213-1218, 2005

20) Carmona L, Descalzo MA, Pampin PE, Montesinos RD, Erra A, Cobo T, Reino GJJ : All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66 (7) : 880-885, 2007

21) Dixon WG, Symmons DP : What effects might anti-TNF alpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? areview of the role of TNF alpha in cardiovascular pathophysiology. Ann Rheum Dis 66 (9) : 1132-1136, 2007

22) Hulimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Behir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Lucher TF, Gay S, Ruschitzka F. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 22 ; 106 (17) : 2184-2187, 2002

23) Del Porto F, Lagana B, Lai S, Nofroni I, Tinti F, Vitale M, Podesta Mitterhofer AP, D'Amelio R : Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 46 (7) : 1111-1115, 2007

24) Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF : Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32 (2) : 252-255, 2005

25) Dominguez H, Storgaard H, Madsen RC, Hermann ST, Ihlemann N, Nielsen BD, Spohr C, Kober L, Vaag A, Pedersen TC : Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42 (6) : 517-525, 2005

26) Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N : Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17 (5) : 385-390, 2007

27) Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwarzinger I, Wolozcszuk W, Steiner G, Smolen JS : Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111 (2) : 204-211, 2005

II. 期待される多様な分野への臨床応用

P.70 掲載の参考文献

1) Maini RN, Brennan FM, Williams R, Chu CQ, Cope AP, Gibbons D, Elliott M, Feldmann M : TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 11 (Suppl 8) : S173-175, 1993

2) van DuUemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J : Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 : 129-135, 1995

3) Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ : Ashort-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 : 1029-1035, 1997

4) D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P : Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease : a European multicenter trial. Gastroenterology 116 : 1029-1034, 1999

5) Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ : Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 : 1398-1405, 1999

6) Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ : Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 : 761-769, 1999

7) Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P : Maintenance infliximab for Crohn's disease : the ACCENT I randomised trial. Lancet 359 : 1541-1549, 2002

8) Sands BE, Blank MA, Patel K, van Deventer SJ : Long-term treatment of rectovaginal fistulas in Crohn's disease : response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2 : 912-920, 2004

9) Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB : Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 : 402-413, 2004

10) van Deventer SJ : Transmembrane TNF alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 121 : 1242-1246, 2001

11) Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T : Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 : 1145-1157, 2001

12) Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, Glimcher LH : Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131 : 33-45, 2007

13) Nenci A, Becker C, WuUaert A, Gareus R, van Loo G, Danese S, Huth M, Nikolaev A, Neufert C, Madison B, Gumucio D, Neurath MF, Pasparakis M : Epithelial NEMO Iinks innate immunity to chronic intestinal inflammation. Nature 446 : 557-561, 2007

14) Zaph C, Troy AE, Taylor BC, Berman-Booty LD, Guild KJ, Du Y, Yost EA, Gruber AD, May MJ, Greten FR, Eckmann L, Karin M, Artis D : Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 446 : 552-556, 2007

15) Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, Schulzke JD : Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 53 : 1295-302, 2004

16) Youdlm A, Vasiliauskas EA, Targan Papadakis KA, Ippoliti A, Dubinsky Lechago J, Paavola J, Loane J, Lee Gaiennie J, Smith K, Do J, Abreu MT pilot study of adalimumab in in patients. Inflamm Bowel Dis 10 : 2004

17) Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntoshD, Panaccione R, Wolf D, Pollack P : Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease : the CLASSIC-I trial, Gastroenterology 130 : 323-333 ; quiz 591, 2006

18) Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF : Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease : the CHARM trial. Gastroenterology 132 : 52-65, 2007

19) Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF : Adalimumab induction therapy for Crohn disease previously treated with infliximab : a randomized trial. Ann Intern Med 146 : 829-838, 2007

20) Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A : Arandomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 : 807-818, 2005

21) Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S : Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 : 228-238, 2007

22) Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ : Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 : 239-250, 2007

23) Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR : Etanercept for active Crohn's disease : arandomized, double-blind, placebo-controlled trial. Gastroenterology 121 : 1088-1094, 2001

24) Marzo-Ortega H, McGonagle D, O'Connor P, Emery P : Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 62 : 74-76, 2003

25) Hanauer SB : Top-down versus step-up approaches to chronic inflammatory bowel disease : presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol 2 : 493, 2005

26) GoekooP-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) : arandomized, controlled trial. Arthritis Rheum 52 : 3381-3390, 2005

27) D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D : Early combined immunosupPression or conventional management in patients with newly diagnosed Crohn's disease : an open randomised trial. Lancet 371 : 660-667, 2008

28) Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R : Induction and maintenance infliximab therapy for the treatment of moderate-tosevere Crohn's disease in children. Gastroenterology 132 : 863-873 ; quiz 1165-1166, 2007

29) Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B : Infliximab as rescue therapy in severe to moderately severe ulcerative colitis : arandomized, placebo-controlled study. Gastroenterology 128 : 1805-1811, 2005

30) Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF : Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 : 2462-2476, 2005

31) Ito H, Takazoe M, Fukuda Y, Hibi Kusugami K, Andoh A, Matsumoto Yamamura T, Azuma J, Nishimoto Yoshizaki K, Shimoyama T, Kishimoto T : A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 : 989-996 ; discussion 947, 2004

32) Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W : Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 : 2069-2079, 2004

33) Matsuoka K, Inoue N, Sato T, Okamoto S, Hisamatsu T, Kishi Y, Sakuraba A, Hitotsumatsu O, Ogata H, Koganei K, Fukushima T, Kanai T, Watanabe M, Ishii H, Hibi T : T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut 53 : 1303-1308, 2004

34) Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T : Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 118 : 2269-2280, 2008

35) Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zakuciova M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T : Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55 : 1131-1137, 2006

36) Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre Jp, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T : A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 55 : 1138-1144, 2006

37) Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P : Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 : 1912-1925, 2005

38) Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P : Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 : 362-368, 2005

39) Feagan BG, Sandborn WJ, Hass S, Niecko T, White J : Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol 102 : 2737-2746, 2007

40) Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ : Natalizumab for the treatment of active Crohn's disease : results of the ENCORE Trial. Gastroenterology 132 : 1672-1683, 2007

41) D'Haens G, Daperno M : Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 8 : 506-512, 2006

P.81 掲載の参考文献

1) Lutterotti A, Martin R : Getting specific : monoclonal antibodies in multiple sclerosis. Lancet Neurol 7 : 538-547, 2008

2) StUe O, Marra CM, Jerome KR et al : Immune survemance in multipel sclerosis patients treated with natalizumab. Ann Neurol 59 : 743-747, 2006

3) Niino M, Bodner C, Simard M-L et al : Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59 : 748-754, 2006

4) Larger-Gould A, Atlas SW, Bollen AW et al : Progressive multifocal leukoencephalopathy in apatient treated with natalizumab. N Engl J Med 353 : 375-381, 2005

5) Kleinschmidt-DeMasters BK, Tyler KI : Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 : 369-374, 2005

6) Polman CH, O'Connor PW, Harvrdova E et al : Arandomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 : 899-910, 2006

7) Rudick RA, Stuart WH, Calabresi PA et al : Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 : 911-923, 2006

8) Calabrest PA, Giovannoni G, Confavreux C et al : The incidence and significance of antinatalizumab antibodies. Results from AFFIRM and SENTINEL. Neurology 69 : 1391-1403, 2007

9) Van Assche G, Van Ranst M, Sciot R et al : Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 : 362-368, 2005

10) Yousry TA, Major EO, Ryschkewitsch C et al : Evaluation of patients treated with natalizumab for progressive multifocal leukoen-cephalopathy. N Engl J Med 354 : 924-933, 2006

11) Kappos L, Bate D, Hartung H-P et al : Natalizumab treatment for multiple sclerosis : recommendations for patients selection and monitoring. Lancet Neurol 6 : 431-441, 2007

12) Gold R, Jawad A, Miller DH et al : Expert opinion : guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 187 : 156-158, 2007

13) Hauser S, Waubant E, Arnold DI et al : B-cell depletion with rituximab in relpasing-remitting multiple sclerosis. N Engl J Med 358 : 676-688, 2008

14) Bar-Or A, Calabresi P, Arnold DI et al : Rituximab in relapsing-remitting multiple sclerosis : a 72-week, open label, phase I trial. Annn Neurol 63 : 395-400, 2008

15) Antel J, Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis : from pathogenesis to treatment. J Neuroimmunol 2006 ; 180 : 3-8.

16) Magliozzi R, Howell O, Vora A et al : Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130 : 1089-1104, 2007

17) McFarland HF : The B cell-old player, new position on the team. N Engl J Med 358 : 664-665, 2008

18) Coles AJ, Cox A, Le Page E et al : The window of therapeutic opportunity in multiple sclerosis : evidence from monoclonal therapy. J Neurol 253 : 98-108, 2006

19) Coles AJ, Wing M, Smith S et al : Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354 : 1691-1695, 1999

20) Munteis E, Cano JF, Flores JA et al : Prevalence of autoimmune thyroid disorders in a Spanish multiple sclerosis cohort. Eur J Neurol 14 : 1048-1052, 2007

21) Bielekova B, Richert N, Howard T et al : Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101 : 8705-8708, 2004

22) Rose JW, Watt HE, White AT et al : Treatment of multiple sclerosis with an antiinterleukin-2 receptor monoclonal antibody. Ann Neurol 56 : 864-867, 2004

23) Van Oosten BW, Lai M, Hodgkinson S et al : Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412 : results of arandomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49 : 351-357, 1997

24) Van Oosten BW, Barkhof F, Truyen L et al : Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti. tumor necrosis factor antibody cA2. Neurology 47 : 1531-1534, 1996

P.94 掲載の参考文献

1) ME Reff, K Carner, KS Chambers et al : Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 : 435-445, 1994

2) OW Press, J Howell-Clark, S Anderson et al : Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83 : 1390-1397, 1994

3) Guillaume Cartron, Laurent Dacheux, Gilles Salles et al : Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood 99 : 754-758, 2002

4) Coiffier B, Lepage E, Briere J et al : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (4) : 235-242, 2002

5) Feugier P, Van Hoof A, Sebban C et al : Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma : a Study by the Groupe d'Etude des Lymphomes de l' Adulte. J Clin Oncol 23 : 4117-4126, 2005

6) Pfreundschuh M, TrUmper L, Osterborg A et al : CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : arandomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7 (5) : 379-391, 2006

7) Tobinai K : Monoclonal antibody therapy for B-cell lymphoma : clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Int J Hematol 76 (5) : 411-419, 2002

8) Czuczman MS, Grillo-Lopez AJ, White CA et al : Treatment of patients with low-grade Bcell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 (1) : 268-276, 1999

9) Czuczman MS, Weaver R, Alkuzweny B et al : Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy : 9-year follow-up. J Clin Oncol 22 (23) : 4711-4716, 2004

10) Czuczman MS, Koryzna A, Mohr A et al : Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23 (4) : 694-704, 2005

11) Knox SJ, Goris ML, Trisler K, Negrin R et al : Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2 (3) : 457-470, 1996

12) Witzig TE, White CA, Wiseman GA et al : Phase I/II trial of IDEC-Y2B8 radio-immunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 (12) : 3793-3803, 1999

13) Witzig TE, Gordon LI, Cabanillas F et al : Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioim-munotherapy versus rituximab immunetherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (10) : 2453-2463, 2002

14) Grillo-Lopez AJ : Zevalin : the first radioim-munotherapy approved for the treatment of lymphomaExpert Rev Anticancer Ther 2 (5) : 485-493 (Review), 2002

15) Witzig TE, White CA, Gordon LI et al : Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkln's lymphoma J Clin Oncol 21 (7) : 1263-1270, 2003

16) Press OW, Unger JM, Braziel RM et al : Phase H trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma : five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24 (25) : 4143-4149, 2006

17) Kaminski MS, Tuck M, Estes J et al : 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (5) : 441-449, 2005

18) Press OW, Unger JM, Braziel RM, et al : A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S9911. Blood 102 (5) : 1606-1612, 2003

19) Leonard JP, Coleman M, Kostakoglu L et al : Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23 (24) : 5696-5704, 2005

20) Larson RA, Sievers EL, Stadtmauer EA et al : Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 (7) : 1442-1452, 2005

21) 吉場史朗, 堀田知光, 飛内賢正ほか : 急性骨髄性白血病に対するCMA-676の有効性と安全性の評価-第II相試験の報告-. 臨床血液46 : 171 (733) [抄録], 2005

22) Kell WJ, Burnett AK, Chopra R et al : A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102 (13) : 4277-4283 (Epub 2003 Aug 21), 2003

23) Lundin J, Kimby E, Bjorkholm M, et al : Phase H trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (3) : 768-773, 2002

24) Elter T, Borchmann P, Schulz H et al : Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia : results of a phase II trial. J Clin Oncol 23 (28) : 7024-7031, 2005

25) Faderl S, Thomas DA, O'Brien S et al : Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101 (9) : 3413-3415, 2003 Epub 2003 Jan 9.

26) Kottaridis PD, Milligan DW, Chopra R et al : In vivo CAMPATH-1H prevents graft-versushost disease following nonmyeloablative stem cell transplantation. Blood 96 (7) : 2419-2425, 2000

27) Chakraverty R, Peggs K, Chopra R et al : Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99 (3) : 1071-1078, 2002

28) Kanda Y, Oshima K, Asano-Mori Y et al : In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation with-out ex vivo graft manipulation. Transplantation 79 (10) : 1351-1357, 2005

29) Bonifazi F, Bandini G, Rondelli D et al : Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors : 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (10) : 2942-2947, 2001

30) Bonifazi F, Bandini G, Rondelli D et al : Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. Bone Marrow Transplant 32 (3) : 237-242, 2003

31) Goldhirsch A et al : 10th St. Gallen conference. Progress and promise : highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (7) : 1133-1144 (Review), 2007

32) Simonds HM, Miles D : Adjuvant treatment of breast cancer : impact of monoclonal antibody therapy directed against the HER2 receptor. Expert Opin Biol Ther 7 (4) : 487-491 (Review), 2007

33) Tan-Chiu E, Yothers G, Romond E et al : Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer : NSABP B-31. J Clin Oncol 23 (31) : 7811-7819, 2005

34) Hurwitz H, Fehrenbacher L, Novotny W et al : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (23) : 2335-2342, 2004

35) Tyagi P, Grothey A : Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer : the NO16966 trial. Clin Colorectal Cancer 6 (4) : 261-264, 2006

36) Reddy GK : The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer : interim data from the ECOG 3200 trial. Clin Colorectal Cancer 4 (5) : 300-301, 2005

37) Saltz L, Rubin M, Hochster H et al : Cetuximab (IMC-225) puls irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor. Proc ASCO 20 : 3a, 2001

38) Cunningham D, Humblet Y, Siena S et al : Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (4) : 337-345, 2004

39) Tabernero JM, van Cutsem E, Sustre J et al : An International phase II study of cetuximab in combination with oxaliplation/5-FU/folinic acid (FOLFOX-4) in the first-line treatment of patients with metastatic cololectal cancer expressing EGFR. preliminary results. Proc ASCO 23 : 248a, 2004

40) Sobrero AF, Maurel J, Fehrenbacher L et al : EPIC : phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol 26 (14) : 2311-2319, 2008

P.101 掲載の参考文献

1) Nickoloff BJ, Nestle FO : Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opPotunities. J Clin Invest 113 : 1664-1675, 2004

2) Ettehadi et al : Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96 : 146-151, 1994

3) Gottlieb AB et al : Infliximab induction therapy for patients with severe plaque-type psoriasis : a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 : 534-542, 2004

4) Menter A et al : Adalimumab therapy for moderate to severe psoriasis : arandomized, controlled phase III trial. J Am Acad Dermatol 58 : 106-115, 2008

5) Papp KA et al : A global phase III randomized controlled trial of etanercept in psoriasis : safety, efficacy, and effect of dose reduction. Br J Dermatol 152 : 1304-1312, 2005

6) Papp KA et al : Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis : 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet 371 : 1675-1684, 2008

7) Lebwohl M et al : An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 : 719-727, 2003

8) Gordon KB et al : Efalizumab for patients with moderate to severe plaque psoriasis : a randomized controlled trial, JAMA 290 : 3073-3080, 2003

9) Amagai M et al : Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 104 : 895-901, 1995

10) Amagai M et al : Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67 : 869-877, 1991

11) Salopek TG, Logsetty S, Tredget EE : Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, lifethreatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 47 : 785-788, 2002

12) Schmidt E et al : Rituximab in autoimmune bullous diseases : mixed responses and adverse effects. Br J Dermatol 156 : 352-356, 2007

13) Joly P et al : A single cycle of rituximab for the treatment of severe pemphigus.N Engl J Med 357 : 545-552, 2007

14) Anhalt GJ et al : Paraneoplastic pemphigus. An autoimmune mucocutaneous disease asso. ciated with neoplasia. N Engl J Med 20 : 1729-1735, 1990

15) Heizmann M et al : Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab : report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 66 : 142-144, 2001

P.106 掲載の参考文献

1) Sakane T et al : Current Concepts : Behcet's disease. N Engl J Med 341 : 1284-1291, 1999

2) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G : Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31 : 1362-1368, 2004

3) 稲森由美子, 水木信久 : ベーチェット病の抗TNFα抗体療法. 眼科48 : 489-503, 2006

P.113 掲載の参考文献

1) Gerloni V et al : Facus on adverse events of TNFα blockade in JIA in an open monocentric long. term prospective study of 163 patients. Ann Rheum Dis Online First, Nov 2, 2007

2) Ruperto N et al : A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56 : 3096-313106, 2007

3) Yokota S et al : Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis : a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371 : 998-1006, 2008

4) Burns JC et al : Infliximab treatment for refractory Kawasaki syndrome. J pediatr 146 : 662-667, 2005

5) Caroli F et al : Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) 46 : 473-478, 2007

6) Marks SD et al : Blymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52 : 3168-3174, 2005

7) Megan A et al : Rituximab for the treatment of juvenile dermatomyositis : a report of four pediatric patients : arthritis Rheum 56 : 3107-3111, 2007

III. 現在申請中・開発中の生物学的製剤

P.123 掲載の参考文献

1) Feldmann M, Brennan FM, Maini RN : Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 : 397-440, 1996

2) Walunas TL, Lenschow DJ, Bakker CY et al : CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 : 405-413, 1994

3) Linsley PS, Greene JL, Brady W et al : Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1 : 793-801, 1994

4) Lundy SK, Sarkar S, Tesmer LA et al : Cells of the synovium in rheumatoid arthritis : T lymphocytes. Arthritis Res Ther 9 : 202, 2007

5) LinksLinsley PS, Brady W, Urnes M et al : CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174 : 561-569, 1991

6) Tan P, Anasetti C, Hansen JA et al : Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 177 : 165-173, 1993

7) Finck BK, Linsley PS, Wofsy D : Treatment of murine lupus with CTLA41g. Science 265 : 1225-1227, 1994

8) Sayegh MH, Turka LA : The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338 : 1813-1821, 1998

9) Webb LM, Walmsley MJ, Feldmann M : Prevention and amelioration of collageninduced arthritis by blockade of the CD28 costimulatory pathway : requirement for both B7-1 and B7-2. Eur J Immunol 26 : 2320-2328, 1996

10) Moreland LW, Alten R, Van den Bosch F et al : Costimulatory blockade in patients with rheumatoid arthritis : apilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-41g and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46 : 1470-1479, 2002

11) Kremer JM, Westhovens R, Leon M et al : Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA41g. N Engl J Med 349 : 1907-1915, 2003

12) Kremer JM, Dougados M, Emery P et al : Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept : twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 : 2263-2271, 2005

13) Kremer JM, Genant HK, Moreland LW et al : Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis : arandomized trial. Ann Intern Med 144 : 865-876, 2006

14) Kremer JM, Genant HK, Moreland LW et al : Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58 : 953-963, 2008

15) Genant HK, Peterfy CG, Westhovens R et al : Abatacept inhibits structural damage progression in rheumatoid arthritis : results from the long-term extension of the AIM trial. Ann Rheum Dis 2007 Dec 17 [Epub ahead of print]

16) Genovese MC, Becker JC, Schiff M et al : Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 : 1114-1123, 2005

17) Genovese MC, Schiff M, Luggen M et al : Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67 : 547-554, 2008

18) Weinblatt M, Schiff M, Goldman A et al : Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept : a randomised clinical trial. Ann Rheum Dis 66 : 228-34, 2007

19) Weinblatt M, Combe B, Covucci A et al : Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs : A one-year randomized, placebo-controlled study. Arthritis Rheum 54 : 2807-2816, 2006

P.129 掲載の参考文献

1) Edwards JC, Cambridge G : B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6 : 394-403, 2006

2) Dorner T, Brumester GR : New approaches of B-cell-directed therapy : beyond rituximab. Curr Opin Rheumatol 20 : 263-268, 2008

3) Grimaldi CM, Hicks R, Diamond B : B cell selection and susceptibility to autoimmunity. J Immunol 174 : 1775-1781, 2005

4) Cohen SB, Emery P, Greenwald MW et al : Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks (REFLEX Randamized Evaluation of Long-term Efficacy of rituximab in RA) Arthritis Rheum 54 : 2793-2806, 2006

5) Emery P, Fleischmann R, Filipowicz-Sosnowska A et al : The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment : results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 : 1390-1400, 2006

6) Keystone EC, Emery P, Peterfy CG et al : Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (in press)

7) Tokunaga M, Saito K, Kawabata D et al : Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66 : 470-475, 2007

8) Tanaka Y, Yamamoto K, Takeuchi T et al : A multi-center phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 17 : 191-197, 2007

9) Keogh KA, Wylam ME, Stone JH, Specks U : Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 : 262-268, 2005

10) Hauser SL, Waubant E, Arnold DL et al : HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 : 676-688, 2008

11) Dorner T, Kaufmann J, Wegener WA et al : Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8 : R74, 2006

P.138 掲載の参考文献

1) Mackay F, Schneider P, Rennert, P, Browning J : BAFF AND APRIL : atutorial on B cell survival. Annu Rev Immunol 21, 231-264, 2003

2) Dillon SR, Gross JA, Ansell SM & Novak AJ : An APRIL to remember : novel TNF ligands as therapeutic targets. Natl Rev Drug Discov 5 : 235-246, 2006

3) Mackay F, Silveira PA, Brink R : Bcells and the BAFF/APRIL axis : fast-forward on autoimmunity and signaling. Curr Opin Immunol 19 : 327-336, 2007

4) Parish CR : The role of heparan sulphate in inflammation. Natl Rev Immunol 6, 633-643, 2006

5) Salzer U, Jennings S, Grimbacher B : To switch or not to switch : the opposing roles of TACI in terminal B cell differentiation. Eur J Immunol 37 : 17-20, 2007

6) Sakurai D et al : TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 109 : 2961-2967, 2007

7) Sakurai D et al : TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur J Immunol 37 : 110-118, 2007

8) Zhang L et al : Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency : clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol 120 : 1178-1185, 2007

9) He B et al : Intestinal bacteria trigger T cell-independent immunoglobulin A (2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26 : 812-826, 2007

10) Xu W et al : Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Natl Immunol 8 : 294-303, 2007

11) Hase H et al : BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 103 : 2257-2265, 2004

12) Seyler TM et al : BLyS and APRIL in rheumatoid arthritis. J Clin Invest 115 : 3083-3092, 2005

13) Strand V, Kimberly R. Isaacs JD : Biologic therapies in rheumatology : lessons learned, future directions. Natl Rev Drug Discov 6 : 75-92, 2007

14) Cheema GS, Roschke V, Hilbert DM, Stohl W : Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44 : 1313-1319, 2001

15) Groom J et al : Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109 : 59-68, 2002

16) Vallerskog T et al : Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8 : R167, 2006

17) Tan SM et al : Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 48 : 982-992, 2003

18) Koyama T et al : Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 64 : 1065-1067, 2005

19) Zhang J et al : Cutting edge : a role for Blymphocyte stimulator in systemic lupus erythematosus, J Immunol 166 : 6-10, 2001

20) Pers JO et al : BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050 : 34-39, 2005

21) Stohl W et al : Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 63 : 1096-1103, 2004

22) Koyama T et al : A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology (Oxford) 42 : 980-985, 2003

23) Kawasaki A et al : Role of APRIL (TNFSF13) polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese. Rheumatology (Oxford) 46 : 776-782, 2007

24) Morimoto S et al : Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus : the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 46 : 1083-1086, 2007

25) Edwards JC, Cambridge G : B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Natl Rev Immunol 6 : 394-403, 2006

26) Browning JL : Bcells move to centre stage : novel oPPortunities for autoimmune disease treatment. Natl Rev Drug Discov 5 : 564-576, 2006

27) Levesque MC, St Clair EW : Bcell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 121 : 13-21, quiz 22-23, 2008

28) Stohl W, Looney RJ : B cell depletion therapy in systemic rheumatic diseases : different strokes for different folks? Clin Immunol 121 : 1-12, 2006

29) Cohen SB : Updates from B cell trials : efficacy. J Rheumatol 33 (Suppl 77) : 12-17, 2006

30) Dall' Era M et al : Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus : results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56 : 4142-4150, 2007

31) Cambridge G et al : Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment : relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54 : 723-732, 2006

32) Dorner T, Burmester GR : No B cells-no active RA? Advances in B cell depletion in RA-repeated therapy under conditions of clinical practice. Rheumatology (Oxford) 46 : 563-564, 2007

33) Martin F, Chan AC : B cell immunobiology in disease : evolving concepts from the clinic. Annu Rev Immunol 24 : 467-496, 2006

34) Tiller T et al : Autoreactivity in human IgG+ memory B cells. Immunity 26 : 205-213, 2007

35) Gong Q et al : Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 : 826, 2005

P.145 掲載の参考文献

1) Rodan GA, Martin TJ : Role of osteoblast in hormonal control of bone resorption : a hypothesis. Calcif Tissue Inte 33 : 349-351, 1981

2) Tanaka S et al : Macrophage colony-stimulation factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 91 : 257-263, 1993

3) Niida S et al : Vascular endothelial growth factor can substitute for macrophage colonystimulating factor in the support of osteoclast bone resorption. J Exp Med 190 : 293-298, 1999

4) Wong BR et al : TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells. J Biol Cehm 272 : 25190-25294, 1997

5) Yasuda H et al : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 : 165-176, 1998

6) Boyle WJ et al : Osteoclast differentiation and activation. Nature 42 : 337-342, 2003

7) Tanaka S : Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system. Am J Nephrology 27 : 466-478, 2007

8) Kong YY et al : Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 : 304-309, 1999

9) Pettit AR et al : TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J pathol 159 : 1689-1699, 2001

10) Xing L et al : Osteoclast precursors, RANKL/RANK, and immunology. Immunological Revews 208 : 19-29, 2005

11) McClung MR et al : Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 : 821-831, 2006

書評

書評を投稿する

最近チェックした商品履歴

Loading...